肺移植患者围术期输血的影响因素分析

doi:10.3969/j.issn.1671-2587.2021.05.003

临床输血与检验 ›› 2021, Vol. 23 ›› Issue (5): 556-560.DOI: 10.3969/j.issn.1671-2587.2021.05.003

• 组织器官移植输血专题（一） • 上一篇下一篇

肺移植患者围术期输血的影响因素分析

王文静, 刘希曦, 芦宏凯, 王琪, 王璐璐, 郭伟洁, 曹永彤

100029 北京,中日友好医院输血科（王文静,刘希曦,芦宏凯,王琪,王璐璐,郭伟洁,曹永彤）; 中日友好医院检验科（曹永彤）

收稿日期:2021-07-23 出版日期:2021-10-20 发布日期:2021-10-20
通讯作者: 曹永彤,男,主任医师,硕士生导师,主要从事临床检验技术和输血治疗与安全方面的研究,（E-mail）caoyongtong92@sina.com。
作者简介:王文静（1987-）,女,内蒙古人,技师,医学学士,主要从事输血相容性检测和器官移植配型方面的研究,（E-mail）wenjing881216@163.com 。

Independent Risk Factors of Perioperative Blood Transfusion in Lung Transplantation

WANG Wen-jing, LIU Xi-xi, LU Hong-kai, et al

Department of Transfusion, China-Japan Friendship Hospital,Beijing 100029

Received:2021-07-23 Online:2021-10-20 Published:2021-10-20

摘要/Abstract

摘要： 目的本文通过分析肺移植患者围术期的实验室检查、手术和出凝血情况,找出肺移植患者围术期输血的独立危险因素,为临床预测用血和合理备血提供依据。方法回顾性分析我院2017年7月~2020年7月完成的260例肺移植患者的临床资料。根据患者围术期是否输注异体血,将患者分为无输血组（n=46）和输血组（n=214）,对两组患者的临床资料、实验室检查情况进行比较。统计患者的基本信息、手术情况、术前和术后实验指标及体外膜肺氧合相关信息,进行单因素和二元Logistic回归分析,确定影响输血的危险因素。结果两组患者临床资料单因素分析在病程>7年（P<0.05）、ASAⅣ级（P<0.01）、双肺移植（P<0.001）、供体冷缺血时间>340 min（P<0.05）、肺移植手术时长>250 min（P<0.001）、术中出血量>400 mL（P<0.001）、术前Hb降低（P<0.05）、术前Hct降低（P<0.05）、术前PT>15 s（P<0.05）、术后PT>15 s（P<0.05）、术后PTA<80%（P<0.05）、术后APTT>43.5 s（P<0.001）方面的差异具有统计学意义。把单因素分析中P<0.1的指标纳入二元Logistic回归分析,结果显示,术后第一次APTT>43.5 s、双肺移植、术中出血量>400 mL、使用ECMO、病程年>7年是肺移植患者围术期输血的独立危险因素。结论术后第一次APTT>43.5 s、双肺移植、术中出血量>400 mL、围术期使用ECMO循环支持、病程超过7年会增加肺移植患者输血风险。充分评估手术方式,改善术前凝血功能和血红蛋白水平,有助于临床科学合理备血。

关键词: 肺移植, 体外膜肺氧合, 异体输血, 凝血功能

Abstract: Objective This study was to define independent risk factors of perioperative blood transfusion in patient who need a lung transplant using laboratory findings,operation methods and bleeding complications to provide the basis for clinical prediction of blood use and blood products preparation. Methods The medical records of 260 lung transplant patients in our hospital from July 2017 to July 2020 were retrospectively reviewed. These patients were divided into non-transfusion group（n=46）and blood transfusion group（n=214） according to receipt of perioperative blood transfusion. The clinical data and laboratory examinations were compared between two groups. Clinical and laboratory variables,such as patients' basic information,surgical conditions,preoperative and postoperative laboratory examinations,and extracorporeal membrane oxygenation（ECMO） related information,were compared using univariate analysis,and binary logistic regression were performed. Results In the univariate analysis,the difference between the two groups in disease course more than 7 years（P<0.05）,ASA Ⅳ（P<0.01）,double lung transplantation（P<0.001）,donor cold ischemia time>340 min（P<0.05）,lung transplantation duration>250 min（P<0.001）,blood loss>400 mL（P<0.001）,preoperative Hb reduction（P<0.05）,preoperative Hct reduction（P<0.05）,preoperative PT>15 s（P<0.05）,postoperative PT>15 s（P<0.05）,postoperative PTA<80%（P<0.05）,postoperative APTT>43.5 s（P<0.001）showed statistically significant.The index of P<0.1 in univariate analysis were performed in binary logistic regression analysis. The results showed that the postoperative APTT>43.5 s, double lung transplantation,intraoperative blood loss>400 mL,ECMO use,disease course>7 years were independent risk factors for perioperative blood transfusion in lung transplantation. Conclusion The postoperative APTT>43.5 s, double lung transplantation,intraoperative blood loss>400 mL, perioperative use of ECMO,and disease duration more than 7 years increased risk for blood transfusion. Evaluation of surgical methods and improvement of preoperative coagulation function and hemoglobin level are conducive to prepare blood products.

Key words: Lung transplantation, ECMO, Allogenetic transfusion, Coagulation function

中图分类号:

R457

王文静, 刘希曦, 芦宏凯, 王琪, 王璐璐, 郭伟洁, 曹永彤. 肺移植患者围术期输血的影响因素分析[J]. 临床输血与检验, 2021, 23(5): 556-560.

WANG Wen-jing, LIU Xi-xi, LU Hong-kai, et al. Independent Risk Factors of Perioperative Blood Transfusion in Lung Transplantation[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(5): 556-560.

参考文献

[1] YUSEN RD, EDWARDS LB, DIPCHAND AI, et al.The Registry of the International Society for Heart and Lung Transplantation: thirty-third adult lung and heart-lung transplant report-2016; focus theme: primary diagnostic indications for transplant[J]. J Heart Lung Transplant,2016,35(10):1170-1184.
[2] CERNAK V,OUDE LANSINK-HARTGRING A,VAN DEN HEUVEL E R,et al.Incidence of massive transfusion and overall transfusion requirements during lung transplantation over a 25-year period[J].J Cardiothorac Vasc Anesth,2019,33(9):2478-2486.
[3] KAYAWAKE H,CHEN-YOSHIKAWA T F,GOCHI F,et al.Postoperative outcomes of lung transplant recipients with preformed donor-specific antibodies[J].Interact Cardiovasc Thorac Surg,2021,32(4):616-624.
[4] HIRANO R,NAMAZUDA K,HIRATA N.Double filtration plasmapheresis: Review of current clinical applications[J].Ther Apher Dial,2021,25(2):145-151.
[5] HUDDLESTON S J,JACKSON S,KANE K,et al.Separate effect of perioperative recombinant human factor VIIa administration and packed red blood cell transfusions on midterm survival in lung transplantation recipients[J].J Cardiothorac Vasc Anesth,2020,34(11):3013-3020.
[6] ISLAM A K,SINHA N,DEVOS J M,et al.Early clearance vs persistence of de novo donor-specific antibodies following lung transplantation[J].Clin Transplant,2017,31(8): e13028. DOI:10.1111/ctr.13028.
[7] SCHMITZER M,WINTER H,KNEIDINGER N,et al.Persistence of de novo donor-specific HLA-antibodies after lung transplantation:a potential marker of decreased patient survival[J].HLA,2018,92(1):24-32.
[8] YETER R,KEMPER D,NAVASARDYAN A,et al.Bloodless lung transplantation: a single center experience[J].Transplant J,2012,94(10S): 950.
[9] CLIFFORD L,KOR D J.Transfusion-associated circulatory overload[M]//Transfusion in the Intensive Care Unit.Cham: Springer International Publishing,2014: 171-182.
[10] DYKES A,SMALLWOOD D,KOTSIMBOS T,et al.Transfusion-related acute lung injury (Trali) in a patient with a single lung transplant[J].Br J Haematol,2000,109(3):674-676.
[11] VLAAR A P J,KLEINMAN S.An update of the transfusion-related acute lung injury (TRALI): a proposed modified definition and classification scheme definition[J].Indian J Hematol Blood Transfus,2020,36(3):556-558.
[12] ONG L P,THOMPSON E,SACHDEVA A,et al.Allogeneic blood transfusion in bilateral lung transplantation: impact on early function and mortality[J].Eur J Cardiothorac Surg,2016,49(2): 668-674.
[13] ONG L P,SACHDEVA A,RAMESH B C,et al.Lung transplant with cardiopulmonary bypass: impact of blood transfusion on rejection,function,and late mortality[J].Ann Thorac Surg,2016,101(2):512-519.
[14] HUDDLESTON S J,JACKSON S,KANE K,et al.Separate effect of perioperative recombinant human factor VIIa administration and packed red blood cell transfusions on midterm survival in lung transplantation recipients[J].J Cardiothorac Vasc Anesth,2020,34(11):3013-3020.
[15] 陈静瑜,毛文君,杨柯佳,等.肺移植围手术期体外膜肺氧合应用指南(2019版)[J].器官移植,2019,10(4):402-409.
[16] PAGANO D,MILOJEVIC M,MEESTERS M I,et al.2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery[J].Eur J Cardio Thorac Surg,2018,53(1):79-111.
[17] 赵晋,陈静瑜,刘东,等.肺移植治疗终末期慢性阻塞性肺病的术式选择[J].中华器官移植杂志,2018,39(12): 757-760.
[18] ARYAL S,NATHAN S D.Single vs.bilateral lung transplantation: when and why[J].Curr Opin Organ Transplant,2018,23(3):316-323.
[19] NAMKOONG H,ISHII M,MORI T,et al.Clinical and radiological characteristics of patients with late-onset severe restrictive lung defect after hematopoietic stem cell transplantation[J].BMC Pulm Med,2017,17(1): 1-9.
[20] ROSSAINT R,BOUILLON B,CERNY V,et al.The European guideline on management of major bleeding and coagulopathy following trauma: fourth edition[J].Crit Care,2016,20: 100.
[21] KOSTER A,FARAONI D,LEVY J H.Antifibrinolytic therapy for cardiac surgery[J].Anesthesiology,2015, 123(1):214-221.
[22] SEF A V,SEF D,RAJ B,et al.Perioperative transfusion practice in patients undergoing lung transplantation -experience from a 7-year period[J].J Cardiothorac Vasc Anesth,2020,34:S16.
[23] RUBINGER D A,CAHILL C,NGO A,et al.Preoperative Anemia management: what's new in 2020?[J].Curr Anesthesiol Rep,2020,10(2):166-175.
[24] HEINRICH S,LOOP T.Preoperative treatment of Anemia-could an ultra-short-term multimodal approach be beneficial for patients undergoing lung surgery?[J].J Thorac Dis,2019,11(suppl 15):S1913-S1915.
[25] MCMAHON T J,PRYBYLOWSKI A C.Anemia in the patient with chronic lung disease[M]//Management of Anemia.New York,NY: Springer New York,2017: 143-155.

肺移植患者围术期输血的影响因素分析

Independent Risk Factors of Perioperative Blood Transfusion in Lung Transplantation

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	耿文艳, 罗冰, 李晓丹, 肖晴, 黄小亭, 毛曼. 大量输血方案在严重产后出血中的应用探讨[J]. 临床输血与检验, 2021, 23(5): 604-607.
[2]	司念, 李可, 魏晴. 体外膜肺氧合支持下的输血策略[J]. 临床输血与检验, 2021, 23(4): 412-415.
[3]	覃予思, 李元波, 薛颖泓, 姜衡春, 郑泽斌, 陈铃. 自体输血在妇科肿瘤患者手术中的应用分析^*[J]. 临床输血与检验, 2021, 23(3): 314-318.
[4]	许倩文, 薛磊, 汪敏, 强萍, 王丽, 徐慧, 张旭晗, 许汉英, 刘欣, 朱薇波, 蔡晓燕, 刘会兰, 孙自敏, 杨林, 王兴兵. 嵌合抗原受体T细胞治疗血液肿瘤所致凝血障碍及相关因素分析^*[J]. 临床输血与检验, 2021, 23(3): 364-370.
[5]	王文静, 赵儒, 王琪, 陈利达, 陈文慧, 芦宏凯. 肺移植患者血液管理研究进展^*[J]. 临床输血与检验, 2021, 23(3): 404-408.
[6]	刘倩, 王笑欢, 郭凯, 牛子健, 宋珊珊, 郭婧, 马曙轩. 新生儿换血前后实验室指标的变化趋势^*[J]. 临床输血与检验, 2021, 23(2): 177-180.
[7]	姜同灿, 方章华, 任俊娇, 陶峰, 陈红波. 早孕期稽留流产患者凝血功能变化及危险因素分析^*[J]. 临床输血与检验, 2021, 23(2): 227-231.
[8]	王瑞含, 范金波, 周国均, 刘久波. 回收式自体输血对剖宫产妇异体输血及经济效益的影响^*[J]. 临床输血与检验, 2020, 22(5): 487-492.
[9]	王瑞含, 范金波, 周国均, 刘久波. 回收式自体输血在某院剖宫产手术中的应用分析[J]. 临床输血与检验, 2020, 22(4): 380-383.
[10]	连萍红, 陈丰梅, 彭红. 贮存式自体输血对非停跳冠状动脉旁路移植术患者免疫功能及术后恢复的影响[J]. 临床输血与检验, 2020, 22(4): 390-393.
[11]	孙小媛, 徐文莹, 王海燕. 妊娠晚期孕妇自体全血保存期间血液质量变化[J]. 临床输血与检验, 2020, 22(3): 264-268.
[12]	程继勇, 谭家明, 李军文. 低分子肝素治疗AECOPD合并呼吸衰竭的疗效、凝血指标、CK-MB及炎性因子表达的临床观察[J]. 临床输血与检验, 2020, 22(2): 172-176.
[13]	王彦, 杨璐, 潘纪春. 深度自体储血在骨科关节置换术中的应用价值研究[J]. 临床输血与检验, 2019, 21(5): 462-464.
[14]	杨浩, 许军生, 曾湖, 何海权, 冯亦伟. 凝血指标和癌胚抗原表达水平与小细胞肺癌患者生存关系的研究[J]. 临床输血与检验, 2019, 21(4): 417-420.
[15]	周循, 刘小倩, 朱娜娜, 郭建荣. 输血与造血干细胞相关的研究进展^*[J]. 临床输血与检验, 2019, 21(3): 330-332.